"While conventional medicine can often effectively treat
the symptoms, most chronic respiratory sufferers are told that
they simply must learn to 'live with it,'" says Dr. Hardy. "However,
extending conventional medical therapies to include integrative
approaches can be highly beneficial to many sufferers," she
adds.
"This study shows that the best asthma drug can be given
to children without having to worry about any long-term adverse
effects on growth and development," says N. Franklin Adkinson
Jr., M.D., a professor of allergy and clinical immunology and
director of CAMP at Johns Hopkins School of Medicine. "Earlier
studies have shown that moderate doses of inhaled steroids stunt
the growth of children by 1 centimeter per year. Some patients
may be on the medications for 10 years or more, and so this could
have meant that these children would be 4 inches shorter than
their non-asthmatic classmates. The CAMP study clearly shows
that the effect on growth suppression is transient and growth
velocity returns to normal after about a year. A second study
from Denmark in the same issue of the journal confirms this finding."
Although the electronic nebulizer has long been favored by practitioners,
University of Florida clinical pharmacist Leslie Hendeles, wants
parents and physicians to know they have another option; a device
that cheaply and effectively delivers asthma medicine in a fraction
of the time, without the need for electricity and with fewer
side effects.
A broad-ranging survey conducted in Norway among 1600 top athletes
by the Norwegian University of Sport and Physical Education showed
recently just how widespread the damage has been. No less than
one athlete in ten -- regardless of the type of sport -- suffers
from asthma or wheeze.
This was revealed at a postgraduate course on iatrogenic lung
diseases given by Professor Philippe Camus of the University
Medical Centre of Dijon, who is also a member of the Clinical
Assembly of the European Respiratory Society (ERS), organizer
of the Congress.
"Understanding the protective effects of sighing may give
us therapeutic options for asthmatics in the future," says
Alkis Togias, M.D., an associate professor of clinical immunology
and principal investigator of the study, which appears in the
August issue of the Journal of Applied Physiology.
The discovery of how the antibody binds to the mast cell receptor
could lead to the development of a new class of drugs that attack
allergies at their source, preventing the cascade of released
chemicals that leads to the itching, sneezing and congestion
of allergies, the life-threatening respiratory distress of asthma
and anaphylactic shock. Todayís commercial drugs only
treat symptoms once the allergic response is already under way.
It's a low-tech solution for an age-old conundrum. Millions
of Americans have chronic health problems that require daily
treatment, but many fail to take their prescribed medications
consistently, resulting in unnecessary - and sometimes life-threatening
- complications. What's more, their physicians may end up prescribing
more potent or even experimental drugs in the mistaken belief
that the original treatment had been ineffective.
Children who experience asthma symptoms require “pretreatment” (the
use of a prescribed, inhaled medication) before any strenuous
activities. “There are many professional and Olympic athletes
who have asthma,” says Epi Mazzei, R.N., manager of LUNG
LINE ® at National Jewish Medical and Research Center. “With
treatment, they are extremely competitive and have even won gold
medals. They haven’t let asthma stop them.”
“People closest to the fires are most at risk. That’s
why individuals living and working in Los Alamos and local Colorado
communities near Bailey were evacuated,” explains Lisa
Maier, M.D., a physician in the Division of Environmental and
Occupational Health Sciences at National Jewish Medical and Research
Center.
The UI investigators determined that mutations in the toll-like
receptor-4 (TLR4) gene can cause some people to be less responsive
to inhaled endotoxin and less prone to develop an asthma-like
response when exposed to this common environmental contaminant.
The findings were published in the June issue of Nature Genetics.
Called The First National Allergen Survey, the study was led
by scientists at the National Institute of Environmental Health
Sciences (NIEHS), a part of the National Institutes of Health,
and done in collaboration with investigators at the U.S. Department
of Housing and Urban Development; Harvard University, and Westat,
Inc. Early results of the study will be presented at the 96th
International Conference of the American Lung Association/American
Thoracic Society and their Canadian counterparts, Wednesday,
May 10, at the Toronto Convention Center (Area D, Exhibit Hall,
South Building, Level 800). Authors will be available to discuss
the study between 11 a.m. and 1 p.m. |